Afuco™ Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (CAT#: AFC-TAB-009)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human RSV. Palivizumab is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Tested Data
  • Datasheet
  • MSDS
  • COA
SDS-PAGE

Figure 1 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in SDS-PAGE

Figure 1 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in SDS-PAGE

SDS-PAGE analysis of AFC-TAB-009 in reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result, different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.

The purity of AFC-TAB-009 was greater than 95% as determined by SDS-PAGE.

SEC-HPLC

Figure 2 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in HPLC

Figure 2 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in HPLC

The purity of AFC-TAB-009 was greater than 94% as determined by SEC-HPLC

Lectin WB

Figure 3 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in Lectin WB

Figure 3 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in Lectin WB

Western blot analysis of AFC-TAB-009 was performed and fucose was detected by AOL-Biotin and SA-HRP. The result was negative, which indicates that there is almost no fucose produced.


Lane 1: Reducing AFC-TAB-009 (2 μg)
Lane 2: Reducing positive control antibody (2 μg)

Lectin ELISA

Figure 4 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in Lectin ELISA

Figure 4 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in Lectin ELISA

Lectin ELISA analysis of AFC-TAB-009 was conducted and fucose was detected using AOL-Biotin and SA-HRP

The result indicates that there is almost no fucose produced.

WB

Figure 5 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in WB

Figure 5 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in WB

Western blot analysis of AFC-TAB-009 was performed by loading RSV F.

AFC-TAB-009 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-anti-human IgG
Lane 1: Reducing Antigen (0.1 μg)
Lane 2: Reducing Antigen (0.3 μg)
Lane 3: Reducing Antigen (0.6 μg)

ELISA

Figure 6 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in ELISA

Figure 6 Afuco Anti-RSV F ADCC Recombinant Antibody (Palivizumab), ADCC Enhanced (AFC-TAB-009) in ELISA

ELISA analysis of AFC-TAB-009 was performed by coating with RSV F.

The secondary antibody: HRP-anti-human IgG


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Humanized (from mouse)
  • Type
  • ADCC enhanced antibody
  • Specificity
  • Tested positive against native RSV antigen
  • Species Reactivity
  • RSV
  • Clone
  • Palivizumab
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC
  • Conjugate
  • Unconjugated
  • Trade name
  • Synagis
  • Generic Name
  • Palivizumab
  • Related Disease
  • Respiratory Syncytial Virus (RSV) disease

Product Property

  • Purity
  • >95% by SDS-PAGE
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

  • Alternative Names
  • Palivizumab; synagis; 188039-54-5; MEDI-493; humanized MAb1129; DB00110RSV; F; Fusion protein (F); NP_044596.1; UniProt ID: O09720; O09720; Entrez: 1494475; Entrez Gene: 1494475; Gene ID: 1494475; Palivizumab; Synagis; Palivizumab

Related Resources

  • Biosimilar Overview
Please refer to Palivizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Palivizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Palivizumab"

Anti-RSV Recombinant Antibody (Palivizumab)
Recombinant monoclonal antibody to Human RSV. Palivizumab is a monoclonal antibody produced by recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab is a humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV.

See other products for "RSV F"

Humanized Antibody

CAT Product Name Application Type
TAB-009 Anti-RSV Recombinant Antibody (Palivizumab) IF, IP, Neut, FuncS, ELISA, FC, WB IgG1 - kappa
TAB-709 Anti-RSV glycoprotein F Recombinant Antibody (Motavizumab) IF, IP, Neut, FuncS, ELISA, FC, WB IgG1 - kappa
MRO-1209LC Anti-HRSV F Recombinant Antibody (MEDI-493) ELISA, Neut, PK Humanized antibody
MRO-1209LC-S(P) Anti-HRSV F Recombinant Antibody scFv Fragment (MEDI-493) ELISA Humanized antibody
MRO-1209LC-F(E) Anti-HRSV F Recombinant Antibody Fab Fragment (MEDI-493) ELISA Humanized antibody

Recombinant Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-709 Afuco™ Anti-RSV F ADCC Recombinant Antibody (Motavizumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody

MHC Tetramer for Virology

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-TAB-009. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare